SUPERNUS PHARMACEUTICALS, INC.
For the period ended Mar 31, 2026. Filed May 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 5, 2026
SUPN$28.75+4.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Stockholders Equity
(unaudited, in thousands, except share data)
| j · Common Stock · Additional Paid-in Capital · Accumulated OtherComprehensiveLoss · RetainedEarnings · TotalStockholders'Equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance, December 31, 2025 | 57,457,462 | $57 | $543,825 | $(44) | $517,876 | $1,061,714 |
| Share-based compensation expense related to employee stock purchase plan and share-based awards | — | — | 8,480 | — | — | 8,480 |
| Issuance of common stock related to employee stock purchase plan and share-based awards, net of taxes withheld | 582,259 | 1 | 9,114 | — | — | 9,115 |
| Net loss | — | — | — | — | (2,293) | (2,293) |
| Unrealized loss on marketable securities, net of tax | — | — | — | (211) | — | (211) |
| Balance, March 31, 2026 | 58,039,721 | $58 | $561,419 | $(255) | $515,583 | $1,076,805 |
| Common Stock · Additional Paid-in Capital · Accumulated OtherComprehensiveLoss · RetainedEarnings · TotalStockholders'Equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance, December 31, 2024 | 55,743,095 | $56 | $479,440 | $(189) | $556,426 | $1,035,733 |
| Share-based compensation expense related to employee stock purchase plan and share-based awards | — | — | 8,068 | — | — | 8,068 |
| Issuance of common stock related to employee stock purchase plan and share-based awards, net of taxes withheld | 246,153 | — | (1,299) | — | — | (1,299) |
| Net loss | — | — | — | — | (11,827) | (11,827) |
| Unrealized gain on marketable securities, net of tax | — | — | — | 30 | — | 30 |
| Balance, March 31, 2025 | 55,989,248 | $56 | $486,209 | $(159) | $544,599 | $1,030,705 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.